REGN Quote, Financials, Valuation and Earnings

Bioage Labs has a net margin of 24.22% compared to Regeneron Pharmaceuticals's net margin of --. Regeneron Pharmaceuticals's return on equity of 15.78% beat Bioage Labs's return on equity of --.

Regeneron Pharmaceuticals has a consensus price target of $918.88, signalling upside risk potential of 44.88%. On the other hand Bioage Labs has an analysts' consensus of $6.75 which suggests that it could grow by 79.52%. Given that Bioage Labs has higher upside potential than Regeneron Pharmaceuticals, analysts believe Bioage Labs is more attractive than Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals has a beta of 0.437, which suggesting that the stock is 56.337% less volatile than S&P 500. In comparison Bioage Labs has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Regeneron Pharmaceuticals has a quarterly dividend of $0.88 per share corresponding to a yield of 0.14%. Bioage Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Bioage Labs pays out -- of its earnings as a dividend.

Regeneron Pharmaceuticals quarterly revenues are $3.8B, which are larger than Bioage Labs quarterly revenues of --. Regeneron Pharmaceuticals's net income of $917.7M is higher than Bioage Labs's net income of -$13.6M. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 16.57x while Bioage Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 5.14x versus -- for Bioage Labs. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 24.22% compared to Regeneron Pharmaceuticals's net margin of 32.59%. Regeneron Pharmaceuticals's return on equity of 15.78% beat Eli Lilly and's return on equity of 80.24%.

Regeneron Pharmaceuticals has a consensus price target of $918.88, signalling upside risk potential of 44.88%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 22.35%. Given that Regeneron Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Regeneron Pharmaceuticals is more attractive than Eli Lilly and.

Regeneron Pharmaceuticals has a beta of 0.437, which suggesting that the stock is 56.337% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Regeneron Pharmaceuticals has a quarterly dividend of $0.88 per share corresponding to a yield of 0.14%. Eli Lilly and offers a yield of 0.65% to investors and pays a quarterly dividend of $1.50 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Regeneron Pharmaceuticals quarterly revenues are $3.8B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Regeneron Pharmaceuticals's net income of $917.7M is lower than Eli Lilly and's net income of $4.4B. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 16.57x while Eli Lilly and's PE ratio is 70.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 5.14x versus 16.58x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 24.22% compared to Regeneron Pharmaceuticals's net margin of 23.96%. Regeneron Pharmaceuticals's return on equity of 15.78% beat Merck &'s return on equity of 40.25%.

Regeneron Pharmaceuticals has a consensus price target of $918.88, signalling upside risk potential of 44.88%. On the other hand Merck & has an analysts' consensus of $112.07 which suggests that it could grow by 24.85%. Given that Regeneron Pharmaceuticals has higher upside potential than Merck &, analysts believe Regeneron Pharmaceuticals is more attractive than Merck &.

Regeneron Pharmaceuticals has a beta of 0.437, which suggesting that the stock is 56.337% less volatile than S&P 500. In comparison Merck & has a beta of 0.401, suggesting its less volatile than the S&P 500 by 59.879%.

Regeneron Pharmaceuticals has a quarterly dividend of $0.88 per share corresponding to a yield of 0.14%. Merck & offers a yield of 3.52% to investors and pays a quarterly dividend of $0.81 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Regeneron Pharmaceuticals quarterly revenues are $3.8B, which are smaller than Merck & quarterly revenues of $15.6B. Regeneron Pharmaceuticals's net income of $917.7M is lower than Merck &'s net income of $3.7B. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 16.57x while Merck &'s PE ratio is 13.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 5.14x versus 3.55x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 24.22% compared to Regeneron Pharmaceuticals's net margin of 2.31%. Regeneron Pharmaceuticals's return on equity of 15.78% beat Pfizer's return on equity of 8.91%.

Regeneron Pharmaceuticals has a consensus price target of $918.88, signalling upside risk potential of 44.88%. On the other hand Pfizer has an analysts' consensus of $31.26 which suggests that it could grow by 23.36%. Given that Regeneron Pharmaceuticals has higher upside potential than Pfizer, analysts believe Regeneron Pharmaceuticals is more attractive than Pfizer.

Regeneron Pharmaceuticals has a beta of 0.437, which suggesting that the stock is 56.337% less volatile than S&P 500. In comparison Pfizer has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.954%.

Regeneron Pharmaceuticals has a quarterly dividend of $0.88 per share corresponding to a yield of 0.14%. Pfizer offers a yield of 6.67% to investors and pays a quarterly dividend of $0.43 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Regeneron Pharmaceuticals quarterly revenues are $3.8B, which are smaller than Pfizer quarterly revenues of $17.8B. Regeneron Pharmaceuticals's net income of $917.7M is higher than Pfizer's net income of $410M. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 16.57x while Pfizer's PE ratio is 17.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 5.14x versus 2.27x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.